SciVision Biotech Inc
TWSE:1786
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SciVision Biotech Inc
Current Portion of Long-Term Debt
SciVision Biotech Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SciVision Biotech Inc
TWSE:1786
|
Current Portion of Long-Term Debt
NT$10.2m
|
CAGR 3-Years
104%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
|
|
M
|
Medtecs International Corporation Ltd
SGX:546
|
Current Portion of Long-Term Debt
$770k
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Visco Vision Inc
TWSE:6782
|
Current Portion of Long-Term Debt
NT$157.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
P
|
Pegavision Corp
TWSE:6491
|
Current Portion of Long-Term Debt
NT$47m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
OK Biotech Co Ltd
TWSE:4155
|
Current Portion of Long-Term Debt
NT$59m
|
CAGR 3-Years
74%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
SciVision Biotech Inc
Glance View
SciVision Biotech, Inc. engages in the research, development, and production of hyaluronic acid medical products. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2010-12-29. The firm primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The firm is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The firm operates its business in the Americas, Europe, Asia, Middle East and Africa.
See Also
What is SciVision Biotech Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
10.2m
TWD
Based on the financial report for Dec 31, 2025, SciVision Biotech Inc's Current Portion of Long-Term Debt amounts to 10.2m TWD.
What is SciVision Biotech Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
67%
Over the last year, the Current Portion of Long-Term Debt growth was -93%. The average annual Current Portion of Long-Term Debt growth rates for SciVision Biotech Inc have been 104% over the past three years , 67% over the past five years .
